Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine

British Journal of Anaesthesia

Volumn 100, Issue 5, 2008, Pages 622-630

  Flockton, E A ^a   Mastronardi, P ^b   Hunter, J M ^a   Gomar, C ^c   Mirakhur, R K ^d   Aguilera, L ^e   Giunta, F G ^f   Meistelman, C ^g   Prins, M E ^h  

^a School of Anaesthesia   (United Kingdom)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e HOSPITAL DE BASURTO   (Spain)

^f UNIVERSITY OF PISA   (Italy)

^g CHU NANCY BRABOIS   (France)

^h NV ORGANON   (Netherlands)

Author keywords

Antagonists neuromuscular block, cyclodextrins, sugammadex; Antagonists neuromuscular block, neostigmine; Monitoring, neuromuscular block; Neuromuscular block, rocuronium, cisatracurium; Pharmacodynamics

Indexed keywords

ACETYLGLUCOSAMINIDASE; CISATRACURIUM; FENTANYL; GLYCOPYRRONIUM BROMIDE; NEOSTIGMINE; PROPOFOL; REMIFENTANIL; ROCURONIUM; SUFENTANIL; SUGAMMADEX; ANDROSTANE DERIVATIVE; ATRACURIUM; DRUG DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOGRAPHY; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT; ANESTHETIC RECOVERY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; GENERAL ANESTHESIA; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEUROMUSCULAR SYNAPSE; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; PROSPECTIVE STUDY; TIME;

ADULT; AGED; ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; ANESTHESIA, GENERAL; ATRACURIUM; DOUBLE-BLIND METHOD; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; MALE; MIDDLE AGED; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 43249093192     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen037     Document Type: Article

References (25)

1. Berg H, Viby-Mogensen J, Roed J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41: 1095-103
2. Arbous MS, Meursing AE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005; 102: 257-68
3. Reid JE, Breslin DS, Mirakhur RK, Hayes AH. Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol. Can J Anaesth 2001; 48: 351-5
4. Van Vlymen JM, Parlow JL. The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg 1997; 84: 148-54
5. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Bülow K. Time to peak effect of neostigmine at antagonism of atracurium- or vecuronium-induced neuromuscular block. J Clin Anesth 1995; 7: 635-9
6. Osmer C, Vogele C, Zickmann B, Hempelmann G. Comparative use of muscle relaxants and their reversal in three European countries: a survey in France, Germany and Great Britain. Eur J Anaesthesiol 1996; 13: 389-99
7. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3: 335-48
8. van den Broek L, Proost JH, Wierda JM. Early and late reversibility of rocuronium bromide. Eur J Anaesthesiol 1994; 11: 128-32
9. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Pedersen HS, Jensen EW. Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade. Can J Anaesth 1996; 43: 932-8
10. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002; 114: 276-80
11. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003; 99: 632-7
12. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667-74
13. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006; 96: 36-43
14. Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007; 106: 283-8
15. Vanacker BF, Vermeyen KM, Struys MM, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007; 104: 563-8
16. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase III study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007; 104: 555-62
17. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Anesthesiology 2007; 106: 935-43
18. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104: 569-74
19. Fuchs-Buder T, Claudius C, Skovgaard T, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789-808
20. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003; 98: 1037-9
21. Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 μg/kg). Eur J Anaesth 2007; 24: 125 (Abstract 9AP7-10)
22. Kim KS, Cheong MA, Lee HJ, Lee JM. Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg 2004; 99: 1080-5
23. Kopman AF, Zank LM, Ng J, Neuman GG. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg 2004; 98: 102-6
24. Mirakhur RK, Dundee JW, Jones CJ, Coppel DL, Clarke RS. Reversal of neuromuscular blockade: dose determination studies with atropine and glycopyrrolate given before or in a mixture with neostigmine. Anesth Analg 1981; 60: 557-62
25. Cozanitis DA, Dundee JW, Merrett JD, Jones CJ, Mirakhur RK. Evaluation of glycopyrrolate and atropine as adjuncts to reversal of non-depolarizing neuromuscular blocking agents in a 'true-to-life' situation. Br J Anaesth 1980; 52: 85-9